Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.57 - $30.41
Previous CloseN/A
Volume680.40K
Average Volume (3M)1.69M
Market Cap
$2.34B
Enterprise Value$3.46B
Total Cash (Recent Filing)$552.93M
Total Debt (Recent Filing)$525.27M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Aug 11, 2025EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.75
Shares Outstanding138,100,430
10 Day Avg. Volume1,698,226
30 Day Avg. Volume1,691,477
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)32.88
Price to Sales (P/S)0.00
P/FCF Ratio-18.44
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue56.53
Enterprise Value/Gross Profit-287.15
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$41.00Price Target Upside144.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe FDA accepted the NDA for plozasiran to treat familial chylomicronemia syndrome, setting up Arrowhead for its first approved drug.
Financial PositionArrowhead is well-capitalized with $1.1 billion in cash, funded into 2028, and started to pay down the $400 million term loan with cash inflows from the collaboration.
Market PotentialThe upcoming launch of plozasiran is expected to pave the way for entry into the larger SHTG market, which has significant potential sales.
Bears Say
Regulatory ProcessManagement does not expect ongoing changes in Washington to affect the timing of plozasiran approval.
Stock Price LimitationThere is a low ceiling for shares in the short term due to limited upside for the FCS launch.
Ownership Overview
4.24% Insiders
15.14% Mutual Funds
21.18% Other Institutional Investors
33.71% Public Companies and Individual Investors
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $9.57 and its highest was $30.41 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $2.34B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Aug 11, 2025 which is in 59 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on May 12, 2025. The company reported $2.75 earnings per share for the quarter, beating the consensus estimate of -$0.442 by $3.192.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -0.95.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 138,100,430 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of $2.75 in its last earnings report, beating expectations of -$0.442. Following the earnings report the stock price went up 9.377%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
Arrowhead Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.00 (144.92% Upside)
$41.00 (144.92% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 553.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.06%
12-Months-Change
Fundamentals
Return on Equity
-24.67%
Trailing 12-Months
Asset Growth
64.74%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
ARWR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Arrowhead Pharmaceuticals demonstrated strong financial performance and significant progress in its pipeline, particularly with the upcoming launch of Plozasiran and promising data from clinical trials. However, the company faces regulatory uncertainties and market challenges, with a heavy reliance on partnerships for future revenue. The sentiment is generally positive due to the outweighing highlights.Read More>ARWR Stock 12 Month Forecast
Average Price Target
$41.00
▲(144.92%Upside)
Technical Analysis
Agios Pharma
―
Beam Therapeutics
―
Disc Medicine
―
Kymera Therapeutics
―
Immunocore Holdings
―